Morgan Stanley Issues a Downgrade on Acceleron Pharma (XLRN) Shares. What’s Next?

July 13, 2018 - By Sheila Anderson

Acceleron Pharma Inc. (NASDAQ:XLRN) Logo

Investors sentiment increased to 1.27 in 2018 Q1. Its up 0.18, from 1.09 in 2017Q4. It improved, as 13 investors sold Acceleron Pharma Inc. shares while 39 reduced holdings. 24 funds opened positions while 42 raised stakes. 38.30 million shares or 0.44% more from 38.14 million shares in 2017Q4 were reported.

64,166 are owned by Ptnrs Ltd Liability Corporation. Utd Ser Automobile Association owns 0.01% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 103,861 shares. Raymond James And Assoc owns 9,478 shares for 0% of their portfolio. Jasper Ridge Limited Partnership invested in 12,498 shares. Mutual Of America Mngmt Ltd accumulated 0.04% or 60,170 shares. Morgan Stanley stated it has 122,224 shares or 0% of all its holdings. Qvt Lp holds 1.48% or 373,481 shares in its portfolio. Putnam Invs Lc has 28,588 shares. Tiaa Cref Invest Ltd Llc holds 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 86,811 shares. Moreover, Bnp Paribas Arbitrage has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). Citigroup Inc invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Dekabank Deutsche Girozentrale holds 307,330 shares or 0.08% of its portfolio. Brown Advisory accumulated 296,383 shares. Timessquare Mngmt Ltd Com holds 0.09% or 332,005 shares in its portfolio. Teacher Retirement Of Texas reported 8,494 shares.

Since March 6, 2018, it had 0 buys, and 7 insider sales for $3.31 million activity. On Tuesday, April 3 the insider Quisel John D sold $46,232. Kumar Ravindra also sold $46,205 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, April 3. Another trade for 4,600 shares valued at $176,772 was sold by Sherman Matthew L. 3,500 Acceleron Pharma Inc. (NASDAQ:XLRN) shares with value of $134,395 were sold by Rovaldi Christopher. 37,500 shares valued at $1.55 million were sold by POPS RICHARD F on Tuesday, March 6.

Acceleron Pharma (XLRN) Receives a Downgrade

Equity analysts at Morgan Stanley’s equity division lowered the rating for shares of Acceleron Pharma (XLRN) from a “Overweight” to a “Equal-Weight” on Friday, 13 July.

The stock decreased 2.62% or $1.235 during the last trading session, reaching $45.875. About 274,632 shares traded. Acceleron Pharma Inc. (XLRN) has risen 37.77% since July 13, 2017 and is uptrending. It has outperformed by 25.20% the S&P500.

Analysts await Acceleron Pharma Inc. (NASDAQ:XLRN) to report earnings on August, 2. They expect $-0.61 EPS, up 20.78 % or $0.16 from last year’s $-0.77 per share. After $-0.58 actual EPS reported by Acceleron Pharma Inc. for the previous quarter, Wall Street now forecasts 5.17 % negative EPS growth.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $2.10 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Fool.com which released: “Celgene Investors Breathe a Sigh of Relief After Acceleron’s Success” on June 30, 2018, also Streetinsider.com with their article: “Acceleron Pharma (XLRN) Granted FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular …” published on July 12, 2018, Fool.com published: “A Huge Win Sends Acceleron Pharma Shares Soaring 42%” on June 29, 2018. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: 247Wallst.com and their article: “Top Analyst Upgrades and Downgrades: AT&T, BlackRock, Broadcom, Diageo, Kinross Gold, United Rentals, Williams …” published on July 13, 2018 as well as Benzinga.com‘s news article titled: “Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn’t Buying” with publication date: June 29, 2018.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.